Baxter/Synovis05/19/2012 —
Following the $325MM acquisition of Synovis Life Sciences earlier this year, Baxter will divest the orthopedic and wound biologic business, which was formerly Pegasus Biologics. Synovis acquired the developer of crosslinked equine pericardium